New Horizons in Menopause, Menopausal Hormone Therapy, and Alzheimer's Disease: Current Insights and Future Directions - Takeaways - MDSpire

New Horizons in Menopause, Menopausal Hormone Therapy, and Alzheimer's Disease: Current Insights and Future Directions

  • By

  • Lisa Mosconi

  • Matilde Nerattini

  • Schantel Williams

  • Matthew Fink

  • January 16, 2025

  • 0 min

Share

  • 1

    Menopausal hormone therapy (MHT) may influence Alzheimer's disease (AD) risk based on timing, formulation, and age at initiation.

  • 2

    Randomized clinical trials indicate increased dementia risk with MHT in women aged 65 and older, while midlife estrogen-only therapy shows potential protective effects.

  • 3

    Early intervention in the preclinical stage of AD, particularly during menopause, is crucial for reducing dementia risk in women.

  • 4

    Estrogen deprivation after menopause is linked to accelerated neuronal aging and increased AD pathology, highlighting the need for MHT.

  • 5

    The timing hypothesis suggests that MHT's neuroprotective effects are maximized when started around the onset of menopause.

Original Source(s)

New Horizons in Menopause, Menopausal Hormone Therapy, and Alzheimer's Disease: Current Insights and Future Directions

  • by Lisa Mosconi, Matilde Nerattini, Schantel Williams, Matthew Fink

  • January 16, 2025

Related Content

Optimal Dietary Patterns for Lower Weight Gain and Risk of Obesity Surrounding Menopause

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Side Effects: Salt, Steroids, and Second Brains

So get this: sodium may track with memory decline (in men), steroids might not be “immunosuppressive” in the ICU, and second pregnancies reshape the brain differently than first. Same theme: biology is less binary than we teach it.